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1. Introduction 
Systemic lupus erythematosus (SLE) is an autoimmune disease that primarily affects women 
of childbearing age with 10:1 female to male ratio.(Siegel & Lee, 1973) Any organ can be 
affected by SLE; pulmonary involvement is usually in the latter course of the disease.(Haupt 
et al., 1981; Orens et al., 1994; Quadrelli et al., 2009) It is important to note that lung 
involvement is proportionately more common in men.(Kamen & Strange, 2010) Any part of 
the pulmonary system can be affected including airways, lung parenchyma, pulmonary 
vasculature, pleura and diaphragm.(Gross et al., 1972; Haupt et al., 1981; Kamen & Strange, 
2010; Orens et al., 1994; Quadrelli et al., 2009; Weinrib et al., 1990) If SLE develops after age 49 
years, it has a higher incidence of serositis, pulmonary involvement and mortality.(Boddaert 
et al., 2004) It is difficult to find out the true prevalence of pulmonary complications of SLE 
since many cases are due to infections.(Kamen & Strange, 2010) A recent autopsy study of 90 
patients diagnosed with SLE, according to the American College of Rheumatology, 
pleuropulmonary involvement occurred in 98% of the autopsies. (Quadrelli et al., 2009) The 
most frequent findings were pleuritis (78%), bacterial infections (58%), alveolar hemorrhage 
(26%), followed by distal airway alterations (21%), opportunistic infections (14%) and 
pulmonary thromboembolism (8%), both acute and chronic.(Quadrelli et al., 2009) In a larger 
series, 25% of patients with SLE had clinical and/or radiographic evidence of pulmonary 
involvement.(Pego-Reigosa et al., 2009) 
2. Clinical features 
SLE can affect the lungs in many ways. In the next section we will review the pulmonary 
diseases associated with SLE according to the anatomic involvement. 
2.1 Pleural diseases 
Pleuritis is the most common pleuropulmonary manifestation of SLE.(Orens et al., 1994) It is 
the initial manifestation in 5% to 10%.(Winslow et al., 1958) Symptoms of pleuritis are 
present in 45% to 60% of patients with SLE and may be associated with pleural 
effusion.(Good et al., 1983; Orens et al., 1994; Pines et al., 1985) Pleural effusion in SLE tends 
to be bilateral, small to moderate in size; however, large effusions may occur.(Bouros et al., 
2008) Typical presentation of pleural involvement is pleuritic chest pain (pain that increases 
with inspiration), dyspnea, and fever. Physical examination may reveal pleural friction rub 
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and signs of pleural effusion. Chest X-ray shows blunting of the costophrenic angle. Some 
patients may have asymptomatic pleural effusion. Other causes of pleural effusion such as 
parapneumonic effusion, pulmonary embolism, and heart failure need to be ruled out. 
Pleural fluid analysis is needed to rule out other etiologies and to confirm the diagnosis of 
lupus pleuritis. Pleural fluid is exudative (elevated pleural fluid protein and lactate 
dehydrogenase levels) when analyzed. Cell counts are elevated with predominance of 
lymphocytes or neutrophils. Pleural fluid glucose level is low, but not as low as in patients 
with rheumatoid arthritis. Special tests reveal low pleural complement level and positive 
anti-nuclear antibody (ANA). These tests are not sensitive enough to rule out lupus pleuritis 
when tests are negative. (Hunder et al., 1972; Small et al., 1982) Pleural fluid ANA titer ≥ 
1:160 and pleural fluid / serum ANA ratio of ≥ 1 strongly support the diagnosis.(Good et 
al., 1983) The finding of lupus erythematosus cells in pleural fluid confirms the diagnosis; 
however this test is rarely performed.(Kamen & Strange, 2010) Pleural biopsy is rarely 
needed, if done it will show a peculiar immunofluorescent pattern characterized by 
staining of nuclei with anti-IgG, anti-IgM and anti-C3.(Pertschuk et al., 1977) Patients with 
pleural disease usually respond to nonsteriodal anti-inflammatory drugs (NSAIDs). Low 
doses of oral glucocorticoids hasten the resolution. Small asymptomatic effusions usually 
resolve without treatment.(Winslow et al., 1958) NSAIDs are sufficient for mild cases; for 
severe cases or for patients on steroids, giving higher doses of steroid is required.( Orens 
et al., 1994; Wiedemann & Matthay, 1989) In refractory pleural effusions tetracycline or 
talc pleurodesis can be an alternative option.( Gilleece et al., 1988; Kaine, 1985; McKnight 
et al., 1991)  
2.2 Parenchymal lung disease 
2.2.1 Acute lupus pneumonitis 
Acute lupus pneumonitis (ALP) is an uncommon but well recognized complication of SLE. 
There is some controversy over the definition ALP.(Swigris et al., 2008) In two recent series, 
the prevalence of ALP in patients with SLE was 2% to 8%.( Kim et al., 2000; Mochizuki et al., 
1999) It is difficult to estimate the exact prevalence given the significant clinical and 
radiological overlap between ALP, bacterial pneumonia and alveolar hemorrhage. ALP 
tends to affect younger patients and those with recent diagnosis of SLE. In 50% of patients 
with SLE who develop ALP, the pulmonary complication is the initial presentation of 
lupus.(Matthay et al., 1975) Clinical presentation includes abrupt onset of fever, cough, 
dyspnea, pleuritic chest pain and occasionally hemoptysis.(Matthay et al., 1975) Physical 
examination usually reveals signs of hypoxia and bibasilar crackles. Radiographic findings 
include bilateral alveolar infiltrates with predominance in lower lung fields (figure 1). 
Pleural effusion occurs in half of the cases.(Matthay et al., 1975) Rarely the initial chest 
radiograph may be normal or may show pulmonary nodules.(Susanto & Peters, 1997) CT 
scan of the chest may show diffuse ground glass opacities and areas of 
consolidation.(Swigris et al., 2008) A fulminant form of ALP may occur during 
pregnancy.(Comer et al., 1996)  The clinical and radiographic features are not specific. Other 
causes of alveolar infiltrates like infectious pneumonia, alveolar hemorrhage, pulmonary 
edema, and organizing pneumonia should be considered. It is important to rule out 
infectious complications. Many of these patients are on systemic steroids and other 
immunosuppressive medications and are at increased risk of opportunistic infections. Early 
bronchoscopy and bronchoalveolar lavage (BAL) with or without transbronchial biopsy is 
mandatory in most cases. BAL should be sent for cell count and differential, bacterial, fungal 
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and viral culture, cytology and for Pneumocystis jiroveci stain. Occasionally a thoracoscopic 
lung biopsy may be needed. The pathological findings are not specific. The most common 
findings include diffuse alveolar damage (DAD) with or without alveolar hemorrhage and 
capillaritis.(Harvey et al., 1954; Keane & Lynch, 2000) Other pathologic features include 
alveolar wall injury, alveolar edema, hyaline membrane formation, immunoglobulin and 
complement deposition. There seems to be some association between ALP and anti-Ro/SSa 
antibodies. One study showed that patients with SLE and pulmonary complications had an 
81% positive result for anti-Ro/SSa antibodies, while patients without pulmonary 
involvement had a 38% positive antibody.(Boulware & Hedgpeth, 1989) A more recent 
review confirmed this association (Mochizuki et al., 1999) The high frequency of anti-Ro/SSa 
antibodies raises the possibility of their role in the pathogenesis of ALP.(Cheema & 
Quismorio, 2000) Prognosis is poor, with mortality reaching up to 50% as reported in an old 
study.(Matthay et al., 1975) The outcome is worse if ALP occurs postpartum.(Matthay et al., 
1975) Eosinophilia or neutrophilia on BAL carries worse prognosis than lymphocytosis.(Witt 
et al., 1996) Because infectious causes can’t be ruled out, empiric broad spectrum antibiotics 
should be started immediately and continued until infection is excluded. There are no 
randomized clinical trials for the treatment of ALP, however it is agreed on that the main 
treatment is systemic corticosteroids (prednisone 1-1.5 mg/kg/day). If no adequate 
response within 72 hours, treatment should be with intravenous pulse steroids (1g 
methylprednisolone daily for three days).(Kamen & Strange, 2010) Additional 
immunosuppresants such as cyclophosphamide should also be considered. In patients 
refractory to corticosteroids, intravenous immunoglobulin, plasma exchange or rituximab 
can be of some help with very little evidence (Eiser & Shanies, 1994; Lim et al., 2006; Pego-
Reigosa et al., 2009; Winder et al., 1993) 
 
 
Fig. 1. Chest X-ray showing diffuse alveolar infiltrates in a patient with acute lupus 
pneumonitis 
2.2.2 Diffuse alveolar hemorrhage 
Diffuse alveolar hemorrhage (DAH) is a rare complication of SLE. ( Badsha et al., 2004; 
Eagen et al., 1978; Zamora et al., 1997) Its prevalence among SLE patients ranges between 
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<2% and 5.4 % (Santos-Ocampo et al., 2000; Zamora et al., 1997), and the mortality rate 
ranges between 50% to 90%.( Erickson et al., 1994; Schwab et al., 1993) Usually it occurs in 
established disease, especially with lupus nephritis.(Zamora et al., 1997) Other 
extrapulmonary manifestations occur with variable degree.(Abud-Mendoza et al., 1985; 
Barile et al., 1997; Koh et al., 1997; Liu et al., 1998; Myers & Katzenstein, 1986; Schwab et al., 
1993; Zamora et al., 1997) However it can occasionally be the initial presentation of 
SLE.(Zamora et al., 1997) Risk factors thought to be contributing to the development of DAH 
are higher titer of circulating anti-DNA antibody, active extra-pulmonary disease, and 
established SLE diagnosis.(Orens et al., 1994)   
Clinical presentation of patients with DAH is not specific; symptoms include acute 
shortness of breath, cough, hemoptysis and fever. The absence of hemoptysis doesn’t rule 
out DAH. In fact hemoptysis is only present in 54% of patients.(Santos-Ocampo et al., 2000) 
Fever is present in more than 80% of patients.(Santos-Ocampo et al., 2000) Signs of 
respiratory distress and hypoxia are noted upon physical examination. Chest radiograph 
shows bilateral alveolar infiltrates. Unilateral pulmonary infiltrates is noted in up to 
18%.(Santos-Ocampo et al., 2000) CT imaging demonstrates new bilateral ground glass 
opacities and consolidation. Acute drop in hemoglobin is frequently encountered. In most 
series anemia was noted >90 of all episodes of DAH. (Abud-Mendoza et al., 1985; Barile et 
al., 1997; Koh et al., 1997; Liu et al., 1998; Myers & Katzenstein, 1986; Schwab et al., 1993; 
Zamora et al., 1997) If diffusion capacity for carbon monoxide (DLCO) is measured it will be 
elevated due to the excess hemoglobin in the alveolar spaces. An increase of DLCO by 30% 
or a value of >130% predicted suggest DAH in the right clinical setting.(Carette et al., 1984; 
Dweik et al., 1997; Ewan et al., 1976; Harmon & Leatherman, 1988;  Leatherman et al., 1984; 
Young, 1989) Low complement level is found in more than 70% of all episodes of DAH.( 
Koh et al., 1997; Liu et al., 1998; Myers & Katzenstein, 1986; Santos-Ocampo et al., 2000; 
Schwab et al., 1993;) Magnetic resonant imaging (MRI) is another imaging study that can 
suggest the presence of blood in the alveoli given the paramagnetic effect of iron.(Hsu et al., 
1992) BAL is mandatory to rule out infection and help in the diagnosis of DAH.  BAL can 
confirm the diagnosis if bloody return increases with serial aliquots. BAL should be 
evaluated for the presence of hemosiderin-laden macrophages, their presence indicate 
alveolar hemorrhage. Transbronchial biopsy (TBBx) may be attempted in stable patients. 
Unfortunately many of these patients require ventilatory support and may not be able to 
sustain the complication of TBBx. Thoracoscopic lung biopsy is rarely needed. Two 
pathological patterns have been described. Bland hemorrhage is more common and occurs 
in 72% while capillaritis occurs in 14% of the times. Both pathological patterns are associated 
with intra-alveolar hemorrhage and hemosiderin–laden macrophages.(Myers & Katzenstein, 
1986; Schwab et al., 1993b; Zamora et al., 1997) IgG , C3 or immune complexes deposition 
occurs in 50% of the cases.(Myers & Katzenstein, 1986) There are no randomized control 
trials addressing treatment options for DAH.  Supportive care is highly valued since many 
of these patients end up in the intensive care unit requiring mechanical ventilation. The 
most acceptable regimen include pulse intravenous steroids (methylprednisolone 1gm per 
day for three days) followed by 1mg/kg of oral prednisone plus intravenous 
cyclophosphamide every four weeks.(Schwab et al., 1993a; Swigris et al., 2008) DAH is one of 
the few indications where plasmapharesis has been shown to be effective, especially in 
refractory cases. (Erickson et al., 1994; Santos-Ocampo et al., 2000) Plasmapharesis may 
improve survival in patients who failed treatment with high dose steroids and 
cyclophosphamide.(Erickson et al., 1994) More recently rituximab has been used in 
www.intechopen.com
 Pulmonary Manifestations of Systemic Lupus Erythematosus 
 
317 
refractory cases with promising results.(Pottier et al., 2011) The mean duration of alveolar 
hemorrhage from onset to radiographic resolution is 7.8 days.(Santos-Ocampo et al., 2000) 
DAH is known to recur within the same subject. In one study, recurrence occurred in more 
than 40% of patients.(Santos-Ocampo et al., 2000) 
2.2.3 Chronic interstitial lung disease 
Chronic interstitial lung disease (ILD) is a well-recognized pulmonary manifestation of SLE.  
The prevalence of chronic ILD in symptomatic patients with lupus is 3%.(Haupt et al., 1981; 
Weinrib et al., 1990) The prevalence increases with an increase in the duration of 
SLE.(Jacobsen et al., 1998) It may present as a chronic and insidious disease or it may follow 
the development of ALP (Boulware & Hedgpeth, 1989; Weinrib et al., 1990)  Chronic ILD 
occurs more commonly in men and older patients. Pulmonary fibrosis affects 18% of 
patients above 50 years compared to 2% of patients under 18 years.(Cheema & Quismorio, 
2000) Clinically, patients usually present with gradually progressive shortness of breath. 
Chronic dry cough can be the initial presentation in some patients. Physical examination 
may show fine bibasilar inspiratory crackles, however finger clubbing is rare.(Renzoni et al., 
1997) Spirometry shows restrictive pattern with proportionate reduction in forced 
expiratory volume in one second (FEV1) and forced vital capacity (FVC) with normal or 
increased FEV1/FVC ratio. Lung volumes and DLCO are typically reduced. Early on, the 
only abnormality in pulmonary function test is an isolated reduction in DLCO. Chest 
radiographs may be normal at the beginning. As the disease progresses it may show 
irregular linear opacities and marked interstitial markings. Reduced lung volume is a late 
finding. High resolution CT (HRCT) of the chest may show diffuse ground glass opacities. 
Other features include diffuse interstitial infiltrates, sepal thickening, honeycombing and 
traction bronchiectasis (figure2). The pattern of ILD mimics that of idiopathic interstitial 
pneumonia (IIP). The presence of pleural disease is common in patients with SLE while it is 
rare in IIP. One study attempted to correlate HRCT findings with clinical and pulmonary 
function tests (PFTs). There was no correlation between abnormal HRCT, pulmonary 
symptoms, disease activity and drug therapy.(Fenlon et al., 1996) The PFT findings did not 
correlate with the presence or the severity of ILD on HRCT.(Fenlon et al., 1996) This lack of 
correlation was confirmed in another study.(Sant et al., 1997) The rate of abnormal CT 
findings in asymptomatic patients is high, reaching 30%.(Bankier et al., 1995; Fenlon et al., 
1996; Haupt et al., 1981) There is no current recommendation to screen asymptomatic SLE 
patients with HRCT. Bronchoscopy with BAL is done to rule out infections. Thoracoscopic 
lung biopsy is needed to identify the underlying pathology. Several histopathological 
patterns are known to occur. The most common pattern is non-specific interstitial 
pneumonia (NSIP), cellular, fibrotic or mixed.(Tansey et al., 2004) This pattern is 
characterized by homogeneous infiltration of alveolar walls with large number of 
lymphocytes and plasma cells. Organizing pneumonia, which used to be called bronchiolitis 
obliterans organizing pneumonia (BOOP) has also been reported.(Gammon et al., 1992) 
Lymphoid interstitial pneumonia (LIP) and usual interstitial pneumonia (UIP) are found 
more commonly in patients with secondary Sjögren's syndrome or overlap 
syndrome.(Schattner et al., 2003; Tansey et al., 2004)  There are no placebo control trials to 
guide the treatment of ILD in SLE. Systemic corticosteroids (Prednisone 60mg/d for at least 
four weeks) improved respiratory symptoms and DLCO in the majority of patients when 
followed up for a mean of 7.3 years. (Weinrib et al., 1990) In patients who don’t respond to 
corticosteroids, treatment with cyclophosphamide, azathioprine, or mycophenolate should 
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be considered. Another approach is to start combination therapy; cyclophosphamide and 
oral glucocorticoids for severe cases and oral steroids with azathioprine for less severe 
cases.(Swigris et al., 2008) The prognosis of ILD associated with SLE is better than the 
idiopathic forms.(Renzoni et al., 1997) The course is usually slow and tends to stabilize or 
improve with time.  
2.3 Pulmonary vascular diseases 
2.3.1 Thromboembolic disease 
Patients with SLE are at increased risk of venous thromboembolism (VTE) with a prevalence 
of 9%.(Gladman & Urowitz, 1980) It is usually related to disease activity. Patients with 
antiphospholipid antibodies have an even more increased risk reaching up to 35% to 42%. 
(Love & Santoro, 1990) Antiphospholipid antibodies (aPL) maybe present in up to two 
thirds of patients with lupus.(Ruiz-Irastorza et al., 2004; Somers et al., 2002) The two major 
antibodies that constitute aPL are lupus anticoagulant and anticardiolipin antibodies (IgG or 
IgM). Criteria of diagnosing antiphospholipid syndrome are discussed elsewhere. In 
addition to VTE, patients with antiphospholipid syndrome are at increased risk of recurrent 
abortions, pulmonary hypertension (PH), DAH, acute respiratory distress syndrome 
(ARDS), and cardiac valvular lesions. (Kamen & Strange, 2010; Swigris et al., 2008) If small-
vessel occlusion occurs in three or more organs the condition is known as catastrophic 
antiphospholipid syndrome (CAPS). (Asherson & Cervera, 1995; Asherson et al., 2001; 
Cervera et al., 2007; Cervera & Asherson, 2008) Cardiopulmonary involvement is common 
with this syndrome and it usually results in ARDS ( Asherson et al., 2008; Bucciarelli et al., 
2006) VTE can occur either acutely (deep vein thrombosis or acute pulmonary embolism) or 
chronically resulting in chronic thromboembolic pulmonary hypertension (CTEPH). Clinical 
features and diagnosis of VTE are similar to unprovoked situations. Once VTE develops, 
 
     
Fig. 2. (Left) HRCT chest showing areas of ground glass opacities and traction 
bronchiectasis. Surgical lung biopsy confirmed the diagnosis of non-specific interstitial 
pneumonia (cellular type). (Right) HRCT chest showing interstitial thickening and areas of 
honeycombing.  Fibrotic form of non-specific interstitial pneumonia was evident on lung 
biopsy 
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long term anticoagulation with warfarin and a target INR of 2.0 to 3.0 is highly 
recommended. It used to be recommended to achieve a higher target INR, but in one study, 
high intensity warfarin (target INR 3.0-4.0) was found not superior to moderate intensity 
warfarin (target INR 2.0-3.0). Moderate intensity warfarin had lower rate of major 
bleeding.(Crowther et al., 2003) Recommendation for primary prevention is lacking. Some 
authors use long term low dose aspirin.(Swigris et al., 2008) Patients with CAPS usually 
require systemic glucocorticoids, immunosuppressants, plasmapharesis and intravenous 
immunoglobulin in addition to anticoagulation.(Swigris et al., 2008) Mortality rate can reach 
up to 50%.(Asherson & Cervera, 1995; Asherson et al., 2001, 2008) 
2.3.2 Pulmonary hypertension 
Pulmonary Hypertension (PH) is defined as a mean pulmonary artery pressure (PAP) ≥ 
25mmHg at rest. (McLaughlin et al., 2009)  The prevalence of PH in SLE patients varies 
between 0.5% to 15%. (Asherson & Oakley, 1986; Asherson et al., 1990) In one study, 50 
consecutive patients with SLE were carefully tested by transthoracic echocardiogram to look 
particularly for PH, none was found to have any echocardiographic evidence of PH. In that 
cohort almost one third were found to have an isolated reduction in DLCO, which could be 
a marker of early pulmonary vascular involvement.(Hodson et al., 1983; Gari  et al., 2009) 
The prevalence is definitely lower than those with scleroderma. Raynaud’s phenomenon 
occurs in 75% of SLE associated pulmonary arterial hypertension (PAH) compared to only 
20% of patients with SLE and no PH.(Matthay et al., 1975) The duration of SLE doesn’t 
correlate with the development of PAH.(Asherson & Oakley, 1986; Asherson & Cervera, 
2007) Clinical presentations of SLE associated PAH is similar to idiopathic pulmonary 
arterial pulmonary hypertension (IPAH). Symptoms include dyspnea, fatigue, chest pain 
and lower limb swelling. Physical examination includes jugular venous distension with a 
large v wave, loud pulmonic component  with wide splitting of the second heart sound, 
murmur of tricuspid regurgitation and/or pulmonic insufficiency, and lower limb edema. 
Physical findings may be minimal in mild PH. In patients with suspected PH, transthoracic 
echocardiogram is the best initial diagnostic test. Right ventricular systolic pressure (RVSP) 
which is an approximation of systolic PAP can only be measured if a tricuspid regurgitation 
(TR) signal is detected. TR signal is only available in 30% of population. Although PH is 
more common in SLE patients than general population, other causes of PH need to be ruled 
out. Tests to evaluate for other causes include HIV, hepatitis B and hepatitis C serology, aPL 
antibodies, HRCT chest to evaluate for interstitial lung disease, ventilation perfusion scan 
(V/Q) to look for any evidence of chronic pulmonary emboli leading to CTEPH, and 
polysomnogram if obstructive sleep apnea is suspected. Eventually right heart 
catheterization is required to confirm the diagnosis of PAH and to rule out PH secondary to 
left heart disease. The pathogenesis of SLE associated PAH is not clear; the high prevalence 
of aPL antibodies suggests that thrombosis may play a role. (Prabu et al., 2009) 
Histopathologic changes are identical to IPAH and include plexiform lesions, intimal 
fibrosis, and thickening of the media. In addition, complement and immunoglobulin 
deposits are found in some patients suggesting that immune deposits may be involved in 
the pathogenesis.(Quismorio et al., 1984)  Several aspects need to be considered when it 
comes to treating SLE associated PAH. All patients should receive long term anticoagulation 
especially those with aPL antibodies. Oxygen, diuretics and digoxin should be considered in 
all patients. PH specific therapies used to treat IPAH are also effective in treating SLE 
associated PAH.  Epoprostenol, bosentan, sildenafil, ambrisentan and tadalafil have all been 
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shown to be effective in treating PAH.( Barst RJ et al.,1996; Galie et al., 2005, 2008, 2009; 
Rubin et al., 2004 )  PAH specific therapies were found to improve 6-minute walk distance 
(6MWD) and functional class. 
Adding immunosuppressants may provide further improvement.  Intravenous 
cyclophosphamide (monthly for six months) was shown to be effective. It reduced the 
systolic PAP when measured by transthoracic echocardiogram, and improved 
6MWD.(Gonzalez-Lopez et al., 2004; Jais et al., 2008) Oral glucocorticoids in conjunction with 
immunosuppressants lowered PAP and improved 6MWD.(Tanaka et al., 2002; Sanchez et al., 
2006) It is not very clear when to use immunosuppressants in SLE associated PAH. Patients 
with mild PH may benefit from immunosuppressive therapy while patients with moderate 
to severe PH need PH specific therapy with or without immunosuppressants.(Swigris et al., 
2008) The prognosis of SLE associated PAH is worse than IPAH, with a 5-year survival of 
only 17% compared to 68% in patients with IPAH.(Chung et al., 2006)  Given the rarity of 
PH in patients with SLE, there is no recommendation to screen asymptomatic patients with 
echocardiogram.  On the other hand, patients with scleroderma should have annual 
transthoracic echocardiogram to evaluate for the presence of PH. 
2.3.3 Acute reversible hypoxia 
This is a rare complication of lupus. In one series 27% of hospitalized patients had this 
condition.(Abramson et al., 1991) It is characterized by an abrupt onset of unexplained 
hypoxia and hypocapnea.  Radiographic chest imaging is normal. Ventilation perfusion 
(V/Q) scan doesn’t show any evidence of thromboembolism. Arterial blood gases 
demonstrates an increase in Alveolar-arterial (A-a) PO2 gradient. The pathogenesis of this 
syndrome is not clear, but it is believed to be due to complement activation leading to 
leukoaggregation within pulmonary capillaries.(Abramson et al., 1991; Belmont et al., 1994) 
Plasma C3a level is markedly elevated if measured during the episode.(Abramson et al., 
1991) Most cases respond quickly to high dose of systemic corticosteroids.(Abramson et al., 
1991; Martinez-Taboada et al., 1995) 
2.4 Airway disease 
2.4.1 Upper airway involvement 
Involvement of the upper airways can occur in up to 30% of patients with SLE. A variety of 
disorders have been described including laryngeal mucosal inflammation or ulceration, 
cricoarytenoiditis, vocal cord paralysis, and necrotizing vasculitis.( Langford & Van Waes, 
1997; Teitel et al., 1992) Patients present with hoarseness and or dyspnea. Severe upper 
airway obstruction due to angioedema requiring mechanical ventilation has also been 
reported.(Thong et al., 2001)  Angioedema usually present with lips and mouth swelling, 
dysphagia, odynophagia and breathing difficulty, it could be due to SLE or medications 
used in SLE like angiotensin-converting enzyme inhibitors.(Agah et al., 1997)   Routine chest 
imaging with Chest x-ray and chest CT is usually normal in patients with upper airway 
obstruction. Spirometry may show flattening of the inspiratory or expiratory loop or both 
depending on the location of the obstruction. Specialized imaging of the upper airways with 
3-D reconstruction is important to demonstrate the site of obstruction. Direct visualization 
with fibro-optic laryngoscopy or bronchoscopy is needed to assess for vocal cord mobility. 
Generally, corticosteroid therapy will be effective in case of laryngeal mucosal inflammation 
or ulceration, and vocal cord paralysis.(Smith et al., 1977; Teitel et al., 1992).  In those who 
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don’t respond to glucocorticoids, infectious causes should be considered. Typical pathogens 
are Haemophilus influenzae and streptococcus, other rare infections include Histoplasma, 
coccidioides, cryptococus, blastomycosis and candida.(Toomey et al., 1974)  
2.4.2 Lower airway involvement 
Diseases involving the lower airways in patient with SLE include bronchial wall thickening, 
bronchiectasias and bronchiolitis obliterans (BO). In a prospective study of 34 subjects with 
SLE, HRCT chest showed bronchial wall thickening and bronchiectasias in 21% of patients. 
These changes were predominantly asymptomatic.(Fenlon et al., 1996) Bronchiolar disorders 
are rare.(Pego-Reigosa et al., 2009) Abnormalities in PFTs have been reported in up to two 
thirds of patient with SLE.(Andonopoulos et al., 1988) In one study of 57 consecutive lupus 
patients, mild to moderate airflow obstruction was noted in 16%.(Groen et al., 1992) BO has 
been rarely reported.( Beylot-Barry et al., 1994; Godeau et al., 1991; Kawahata et al., 2008) The 
disease is characterized by severe airflow obstruction that’s mostly irreversible. Patients 
usually have progressive dyspnea. PFTs show reduction in FEV1/FVC ratio. If obstruction 
is severe, gas trapping (elevated residual volume) and hyperinflation (elevated total lung 
capacity) may be noted. HRCT chest shows mosaic attenuation pattern that gets accentuated 
in the expiratory images (figure 3). Histopathologic confirmation is rarely required. Disease 
is usually progressive. Systemic corticosteroids and immunosuppressive therapies have 
been tried with little success.(Beylot-Barry et al., 1994; Kawahata et al., 2008) More recently 
anticholinergics were reported to have a favorable outcome.(Kawahata et al., 2008) 
 
     
Fig. 3. (Left) Inspiratory HRCT scan of a 35 year old woman with SLE and bronchiolitis 
obliterans showing mosaic attenuation. (Right) Expiratory HRCT scan in the same subject 
showing an increase in mosaic pattern indicating small airways disease. 
2.5 Muscular involvement 
Shrinking lung syndrome (SLS) is a rare manifestation of SLE. 77 patients with SLS have 
been reported in the literature, with a prevalence of 0.6% to 0.9%.(Pego-Reigosa et al., 2009; 
Toya & Tzelepis, 2009)  It was first described in patients with lupus who presented with 
unexplained dyspnea, decreased lung volumes and elevation of the diaphragm on 
radiographic imaging and restriction on pulmonary function tests in the absence of any 
parenchymal disease.(Hoffbrand & Beck, 1965; Karim et al., 2002; Warrington et al., 2000) It 
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can rarely be the presenting feature of SLE.(Stevens et al., 1990) The pathogenesis is still 
unclear with conflicting results. One hypothesis is myositis of the diaphragm or phrenic 
neuropathy.( Hardy et al., 2001; Rubin & Urowitz, 1983;) In one study, patients with elevated 
diaphragms had an abnormal transdiaphragmatic pressure, indicating diaphragmatic 
weakness.(Gibson et al., 1977) However normal muscle strength of the diaphragm in 
patients with SLS has been reported.( Hawkins et al., 2001; Laroche et al., 1989) Clinically, 
patients present with dyspnea that is particularly worse when supine. Pleuritic chest pain is 
present in 65% of patients.(Toya & Tzelepis, 2009) Physical examination reveals diminished 
breath sounds at the lung bases with or without basilar crackles. Chest radiographs and CT 
show elevation of both diaphragms with basal linear atelectasis and without any evidence of 
parenchymal lung disease (figure 4). PFT’s show restriction with preserved DLCO corrected 
for alveolar volume (DL/VA). Assessment of respiratory muscles show reduced maximal 
inspiratory pressure (MIP) and stable maximal expiratory pressure (MEP).  Diaphragmatic 
weakness can be established by measuring the transdiaphragmatic pressure or by doing 
electromyography of the diaphragms. Autopsy findings include diffuse fibrosis and atrophy 
of the diaphragms. (Rubin & Urowitz, 1983) There are no randomized clinical trials for the 
treatment of SLS. Several agents have been tried with variable effects. Oral glucocorticoids 
with or without immunosuppressive medications have been shown effective. ( Soubrier et 
al., 1995; Walz-Leblanc et al., 1992) Other treatment options for SLS include theophylline, 
azathioprine, methotrexate, cyclophosphamide and rituximab.( Benham et al., 2010; Karim et 
al., 2002; Soubrier et al., 1995; Toya & Tzelepis, 2009; Van Veen et al., 1993; Walz-Leblanc et 
al., 1992)  Disease usually stabilizes or improves with treatment with good overall 
prognosis.(Martens et al., 1983)  Respiratory failure rarely occurs.(Ernest & Leung, 2010)     
 
 
Fig. 4. Chest X-ray showing gross elevation of both diaphragms in a patient with SLE and 
shrinking lung syndrome 
2.6 Associated lung disorders 
2.6.1 Adult respiratory distress syndrome (ARDS) 
The prevalence of ARDS is 4% to 15% in patients with lupus.(Andonopoulos, 1991; Kim et 
al., 1999) If it develops the mortality rate can reach up to 70%.(Kim et al., 1999)  ARDS 
www.intechopen.com
 Pulmonary Manifestations of Systemic Lupus Erythematosus 
 
323 
related mortality contributes to 30% of all Lupus deaths. The most frequent cause of ARDS 
is sepsis; other causes include ALP, DAH, and CAPS. In lupus patients, ARDS tend to occur 
at a younger age and is more progressive than ARDS in non-SLE patients. (Andonopoulos, 
1991; Kim et al., 1999; Pego-Reigosa et al., 2009) It is important to identify the underlying 
cause. Treatment of ARDS is supportive. 
2.6.2 Infectious complications 
SLE can impair the immune system at multiple levels.(Orens et al., 1994; Rudd et al., 1981 ) 
The clinical significance of this is unknown since the risk of infection in the absence of 
immunosuppression is negligible. Most patients with infectious complications are on 
immunosuppressive drugs. Infections account for 30% to 50% of all deaths of SLE.( 
Bernatsky et al., 2006; Zandman-Goddard & Shoenfeld, 2005;) Bacterial pathogens account 
for 75% of all infections, mycobacteria 12%, fungal infections 7%, and viruses 5%.(Kinder et 
al., 2007) Opportunistic infections such as Pneumocystis jiroveci, Nocardia, Aspergillus and 
Cytomegalovirus have been reported.( Fessler, 2002; Petri, 1998; Zandman-Goddard & 
Shoenfeld, 2005) Clinical picture is indistinguishable from non-infectious complications such 
as ALP and DAH, hence aggressive diagnostic approach is recommended with chest 
imaging, bronchoscopy and BAL. Empiric broad-spectrum antibiotics should be started 
awaiting identification of an organism. Once a pathogen is isolated treatment should be 
tailored accordingly. Risk of infection can be reduced by influenza and pneumococcal 
vaccination.(O'Neill & Isenberg, 2006) Since many patients with SLE require systemic 
glucocorticoids and immunosuppresants at some point, screening for latent Tuberculosis 
(TB) is important, especially in high prevalence areas. This can be done via skin testing or 
interferon gamma release assay (IGRA).  For those taking glucocorticoids, induration of 
5mm or greater is considered a positive tuberculin skin test. If latent TB is identified 
treatment is recommended with a nine month course of Isoniazid. The role of Pneumocystis 
jiroveci pneumonia (PCP) prophylaxis is less clear. It is suggested for those who are on 
heavy immunosuppression.(Li et al., 2006) 
2.6.3 Lung cancer 
Studies have shown an increased risk of lung cancer in patients with SLE.(Bernatsky et al., 
2006; Pego-Reigosa et al., 2009) Histological pattern is similar to that in general population, 
adenocarcinoma being most common. However there is tendency for uncommon thoracic 
malignancies such as carcinoids and bronchoalveolar carcinoma.(Bin et al., 2007; Pego-
Reigosa et al., 2009) 
2.7 Drug reactions 
In this section we will cover two aspects of drugs and SLE. First we will briefly discuss 
drugs that can cause SLE and the associated pulmonary manifestations. After that we  
will elaborate on pulmonary drug toxicity associated with commonly used medications to 
treat SLE.  
Pulmonary manifestations of drug induced lupus are similar to idiopathic SLE.(Cush & 
Goldings, 1985; Yung & Richardson, 1994) Most commonly it presents with pleurisy and 
pleural effusion.(Wiedemann & Matthay, 1989) Common drugs include Procainamide and 
hydralazine. Newer biologic agents such as entanercept have been reported to cause drug 
induced lupus.(Abunasser et al., 2008) 
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Common drugs used to treat lupus and are known to cause pulmonary complications 
include Methotrexate and Cyclophosphamide. 
Pulmonary complications related to methotrexate are rare, estimated less than 1%.(Lateef et 
al., 2005) Methotrexate can cause acute, subacute or chronic lung toxicity. It is usually not 
dose dependent but rather idiosyncratic.(Imokawa et al., 2000; Ohosone et al., 1997)  
Subacute pneumonitis is most common and presents with fever, cough and dyspnea. 
Crackles are usually noted on physical examination. It usually presents within the first year 
of starting the drug. If left unrecognized it can progress into pulmonary fibrosis in up to 
10%.  Radiologic findings are not specific. Ground glass opacities and diffuse interstitial 
infiltrates are frequently noted on HRCT. BAL is needed to rule out infections.  Histologic 
findings include varying degree of inflammation and fibrosis. Ill-defined granulomas, and 
increased tissue eosinophils have been observed. ( Malik et al., 1996; Sostman et al., 1976) 
Once diagnosis is made methotrexate needs to be stooped and systemic steroids should be 
started. Prognosis is usually favorable. 
Cyclophosphamide lung toxicity is also idiosyncratic. It can present as early onset or late 
onset pneumonitis.(Malik et al., 1996) Early onset disease appears within the first six months 
of starting treatment. It presents with non-productive cough, fever and dyspnea. (Pego-
Reigosa et al., 2009) CT chest shows bilateral upper lobe predominant ground glass 
opacities. PFT shows reduction in lung volumes and DLCO. BAL is needed to rule out 
infections. Discontinuing the drug along with systemic glucocorticoids usually improve 
symptoms and lung function.  Late onset pneumonitis usually occurs after several years of 
exposure to cyclophosphamide. It is a slowly progressive disease. It presents with 
progressive dyspnea and dry cough. Chest imaging shows interstitial fibrosis affecting the 
upper lobes. This condition usually does not respond to steroids. Lung transplantation is an 
option in appropriate candidates. 
3. Assessment of patients with dyspnea 
3.1 Assessment of patients with chronic dyspnea 
The work up of patients with SLE and chronic dyspnea can be lengthy (Figure 5). Chronic 
dyspnea can be due to a variety of conditions such as interstitial lung disease related to SLE 
or drugs used to treat lupus, pleural disease, pulmonary hypertension, systolic heart failure, 
upper airway disease, obliterative bronchiolitis, shrinking lung syndrome or chronic 
infections. Certain clues on history can be helpful; for example dyspnea increasing in the 
supine position suggests diaphragmatic involvement due to SLS, dyspnea and hoarseness 
suggest upper airway involvement, Dyspnea with pleuritic chest pain suggests pleuritis 
related to SLE.  All patients require CXR, HRCT chest and full PFT. If chest imaging is 
normal with or without isolated reduction in DLCO, then transthoracic echocardiogram 
should be done to assess for the presence of PH. If PH is detected, patients should not be 
labeled to have SLE associated PAH until other causes have been ruled out. So hepatitis B 
and C serology, HIV testing, and V/Q scan should be done. All patients should have right 
heart catheterization to confirm the presence of PH and to rule out left heart disease. If SLE-
PAH is diagnosed PH specific therapies should be started. If chest imaging shows elevation 
of the diaphragms, especially in the presence of normal DLCO adjusted for alveolar volume, 
shrinking lung syndrome should be suspected. Electromyography or transdiaphragmatic 
pressure measurement should be obtained. Either of these two tests may show evidence of 
diaphragmatic weakness. If confirmed, trial of systemic steroids is advised. The presence of 
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pleural effusion on CXR or CT chest suggests pleural disease associated with SLE. The 
pleural fluid should be analyzed to rule out other causes. In situations where chest imaging 
is normal but there is flattening of the inspiratory loop, expiratory loop or both, upper 
airway obstruction needs to be ruled out. Special imaging of the upper airways is 
recommended. If interstitial changes are the predominant features on chest imaging, 
interstitial lung diseases related to lupus or drugs are the main differential. Bronchoscopy 
with BAL should be done to rule out chronic infections. Thoracoscopic lung biopsy is 
helpful to identify the pathological pattern of involvement. 
3.2 Assessment of patients with acute dyspnea 
Several conditions can predispose patients to episodes of acute dyspnea.  Pulmonary 
infections, ALP, DAH, PE, and acute reversible hypoxia are the major culprits. Assessment 
starts with clinical evaluation. (Figure 6) is a proposed algorithm for work up of patients 
with SLE presenting with acute dyspnea.  Most conditions are indistinguishable on clinical 
bases. The presence of hemoptysis should raise the suspicion of DAH or PE. After clinical 
evaluation and stabilization of the patient it is important to get a CXR. If CXR is normal then 
it is more likely that dyspnea is due to either acute reversible hypoxia or PE. V/Q scan will 
differentiate between the two.  V/Q scan will be normal in the former and it will show 
mismatched perfusion defects in the latter. If CXR shows pleural effusion or wedge shaped  
 
 
Fig. 5. Work-up of patients with SLE presenting with chronic dyspnea. 
bronchoalveolar lavage (BAL); chest x-ray (CXR); diffusion capacity for carbon monoxide 
(DLCO); diffusion capacity for carbon monoxide adjusted for alveolar volume (DL/VA); 
high resolution computed tomography (HRCT); interstitial lung disease (ILD); pulmonary 
arterial hypertension (PAH); pulmonary function test (PFT); pulmonary hypertension (PH); 
right heart catheterization (RHC); shrinking lung syndrome (SLS); systematic lupus 
erythematosus (SLE); video-assisted thorascopic surgery (VATS). 
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Fig. 6. Work-up of patients with SLE presenting with acute dyspnea. 
acute lupus pneumonitis (ALP); bronchoalveolar lavage (BAL); chest x-ray (CXR); computed 
tomography (CT); computed tomography pulmonary angiogram (CTPA); diffuse alveolar 
hemorrhage (DAH); ground-glass opacities (GGO’s); ventilation/perfusion lung scan (V/Q 
Scan) 
* CTPA is done if pulmonary embolism suspected 
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opacities it is important to get CT pulmonary angiogram to look for evidence of PE. If CXR 
shows mainly alveolar infiltrates, CT chest should be considered. In these situations 
bronchoscopy with BAL, with or without TBBX, is highly recommended. The presence of 
hemosiderin laden macrophages confirms the diagnosis of DAH. If TBBX is performed and 
it showed features of DAD, then the likely diagnosis is ALP. BAL should be routinely sent 
for cultures. Empiric antibiotics should be started immediately until the results of cultures 
are known. It is not unusual to start patients on both broad spectrum antibiotics and 
systemic corticosteroids while the work up is being actively pursued. 
4. Conclusion 
SLE can affect many aspects of the pulmonary system. There is significant overlap in the 
clinical presentation of many SLE associated pulmonary conditions. Aggressive work up is 
needed early on to identify the underlying etiology. 
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